Tag Archives: vrtx

Vertex Cystic Fibrosis Success Quells Street’s Doubts

Biotech Vertex Pharmaceuticals (VRTX) said Tuesday that its cystic-fibrosis regimen hit its goals in a late-stage study, sending shares soaring 42% to a 14-year high in the stock market today. Vertex said patients taking a combination of lumacaftor and ivacaftor for 24 weeks showed a statistically significant improvement in lung function, as well as a significant reduction in the rates of pulmonary exacerbations and improvements in body mass. The

Vertex Cystic Fibrosis Trial Has Good, Bad News

Vertex Pharmaceuticals (VRTX) stock fell, then rose, in morning trading Thursday as investors and analysts assessed the results of a Phase III test of its treatment for cystic fibrosis, called Kalydeco. “The study did not meet its primary endpoint,” Vertex said in its press release early Thursday. But the company also said “pre-specified subset analysis in patients 18 years of age and older showed statistically significant improvements in lung